Helomics
Predictive Oncology Announces $4.1M Direct Offering
On Thursday, Predictive Oncology closed another direct offering initiated earlier in the week, raising $2.2 million.
Predictive Oncology Prices $2.2M Direct Offering
The company has reached agreements with investors for a direct offering of 2.2 million shares at $1 per share, for gross proceeds of about $2.2 million.
Predictive Oncology Prices $3.2M Public Offering
The company operates three subsidiaries including Helomics, which provides tumor-analysis services for treatment personalization and new drug development.
Helomics Inks Separate Pacts With UPMC, Interpace Dx for AI-Driven Oncology Decision Making
The groups will use Helomics' artificial intelligence-based platform to develop tools to provide predictive therapeutic recommendations for ovarian and thyroid cancers.
Helomics, ChemImage Partner on Prostate Cancer Monitoring Tech Development
Through the deal, Helomics aims to build a predictive model of prostate cancer drug response based on a combination of genomic and spectroscopy data.
Mar 21, 2019
Viome, Helomics Form Microbiome Analysis Partnership
Jan 12, 2017
Helomics, MDNA Partner on Diagnostics
Dec 21, 2016
Helomics Completes Restructuring to Clinical CRO
Nov 29, 2016
Med BioGene, Helomics Revise Licensing Agreement
Jan 27, 2015